Ivan Cheung, chairman of Eisai’s U.S. operations and global leader of its Alzheimer’s disease division, will retire at the end of the month, the company announced on Tuesday. The unexpected announcement was made just days after Eisai received final U.S. approval for its Alzheimer’s drug, Leqembi.
Keisuke Naito, his 34-year-old brother-in-law and current chief ecosystem officer and chief strategy officer, will replace Cheung as the head of the Alzheimer’s unit. Additionally, he is the son of Eisai CEO Haruo Naito.
The current chief financial officer, Tatsuyuki Yasuno, will replace Cheung as director of Eisai’s U.S. unit.
Unlock this article by subscribing to STAT+ for free for the first thirty days.
